ArticleBMC gastroenterology2026
Association between iron status and inflammation markers with GDF15 and BMP6 in inflammatory bowel disease: a single center cross-sectional study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic disorders with relapsing and remitting disease courses. Several clinical indicators and biomarkers have been evaluated for their clinical utility in assessing disease prognosis and monitoring disease activity. This study evaluated the utility of growth differentiation factor-15 (GDF15) and bone morphogenetic protein-6 (BMP6) in inflammatory pathways and iron regulation in IBD.
methodsBetween September 2015 and March 2016, this single-center, cross-sectional study included 40 CD patients, 29 UC patients, and 70 healthy controls. The disease activity was measured using the Mayo score and the Crohn's Disease Activity Index (CDAI). Serum iron, hematological indices, inflammatory markers, and the novel biomarkers BMP6 and GDF15 as determined by ELISA were evaluated.
resultsBoth the CD and UC groups showed significantly lower serum iron (p < 0.001), reduced mean corpuscular hemoglobin concentration, and higher red cell distribution width than the control group. Inflammatory markers, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), were elevated in IBD, particularly during active disease, with CRP increasing significantly in active UC compared to remission (p = 0.040). In contrast, BMP6 and GDF15 levels did not differ significantly between the disease groups or activity states. Nonetheless, GDF15 demonstrated moderate positive correlations with serum iron (r = 0.314), hemoglobin (r = 0.320), and mean corpuscular hemoglobin concentration (MCHC) (r = 0.344), suggesting a link to erythropoietic or iron-related processes rather than inflammation.
conclusionsConventional markers reliably confirmed iron deficiency and inflammation in IBD. BMP6 and GDF15 levels did not differ significantly across disease states, indicating limited utility as markers of disease activity. Notably, GDF15 was positively correlated with serum iron, hemoglobin, and MCHC, suggesting its association with iron metabolism rather than active inflammation. Larger longitudinal studies are warranted to validate this potential role.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.